

## **Hilleman Laboratories announces creation of new Strategic Advisory Committee**

*Expert panel of global health leaders will help shape next phase of Hilleman's growth*

**New Delhi, 18 January 2019:** Hilleman Laboratories, a global research and development organization focused on delivering high-impact and affordable vaccine solutions, today announced creation of new Strategic Advisory Committee (SAC) to help shape the next phase of Hilleman's growth.

The new SAC is led by Dr. Ted Bianco, former acting Director of Wellcome Trust. Dr. Bianco is a global leader in public health research, advocacy and policy. He is also a founding member of Hilleman Labs.

Assisting Dr. Bianco on the new SAC will be:

- Ms. Mahima Datla, Managing Director of Biological E Limited, India's first private sector biological products company that supplies several essential and lifesaving vaccines and pharmaceuticals to UN Agencies, other global markets, and within India, to Central and State Government Hospitals, Public Sector Undertakings, the Indian Armed Forces and the domestic retail market.
- Dr. Kevin Johnson, co-founder and partner at Medicxi, a life sciences-focused investment firm, investing its two most recent funds, Medicxi Ventures 1 (focus on early-stage companies) and Medicxi Growth 1 (focus on later stage companies), in addition to managing the entire portfolio of all life sciences investments.
- Dr. David Kaslow, Vice President of Essential Medicines at PATH, a global organization consisting of innovators working to accelerate health equity, including advice and partnering with public institutions, businesses, grassroots groups, and investors to solve the world's most pressing health challenges.

- Prof. Andrew Pollard, Professor of Pediatric Infection & Immunity, University of Oxford. Prof. Pollard’s research focuses on design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and studies using a human challenge model of (para)typhoid.
- In addition, Dr. Martin Friede will act as an observer to the SAC. He is coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. Dr. Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and priorities.

Speaking about the creation of the new SAC, Dr. Gerd Zettlmeissl, Chairman of Board of Directors at Hilleman Labs said, “Vaccines play a critical role in improving healthcare outcomes globally. Hilleman Labs is pleased to welcome our distinguished panel of members to the new Strategic Advisory Committee. With their deep knowledge and expertise in global health and policy, I have no doubt the panel will shape future successes at Hilleman Labs in a significant way. I extend a warm welcome to SAC Committee members and look forward to working with them, alongside the Hilleman Labs management team, in creating new avenues for public health impact by developing affordable vaccines”.

The new SAC will meet twice yearly, with its inaugural meeting scheduled for early 2019 in New Delhi.

### **ABOUT HILLEMANN LABORATORIES**

Hilleman Laboratories is a first-of-its-kind joint-venture partnership formed between MSD a global research-driven pharmaceutical organization and Wellcome Trust, a global charitable foundation dedicated to human and animal health by supporting the brightest minds. Hilleman Laboratories has been named after renowned scientist and father of modern vaccines Dr. Maurice Hilleman. His dedication to making a difference through the practical application of vaccine research and delivering vaccines to people in need forms the core mission of Hilleman Laboratories.

Hilleman Laboratories aims to become a global voice for vaccine development and access for public health in the developing world.